A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. We believe therapies that inhibit multiple drivers of disease by targeting fundamental upstream control processes within the cell have the potential for profound therapeutic benefit in a number of difficult-to-treat diseases. To that end, we are advancing a drug development program that harnesses a key regulator of cellular function by targeting the immunoproteasome, which is responsible for protein degradation in cells of the immune system and drives many key aspects of immune cell function. We believe targeting this fundamental regulator of cellular function offers an attractive approach to treating autoimmune diseases. Our product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that we are evaluating for the treatment of severe autoimmune diseases of high unmet medical need.
| Segment | 2023 | % of Total |
|---|---|---|
Collaboration Revenue | $7M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 |
| Net Income | -62M | -84M | -102M | -68M |
| EPS | $-8.44 | $-11.49 | $-14.04 | $-10.10 |
| Free Cash Flow | -57M | -74M | -83M | -60M |
| ROIC | -53.0% | -68.6% | -51.5% | -24.4% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.02 | 0.04 | 0.05 | 0.04 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -66M | -91M | -111M | -71M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -74.4% | -55.0% | -54.3% | -25.3% |
| Shares Outstanding | 7M | 7M | 7M | 7M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -71M | -111M | -91M | -66M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -68M | -102M | -84M | -62M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 12M | 2.9M | 2.9M |
| Returns on Capital | ||||
| ROIC | -24.4% | -51.5% | -68.6% | -53.0% |
| ROE | -25.3% | -54.3% | -55.0% | -74.4% |
| ROA | -22.8% | -46.0% | -45.8% | -63.1% |
| Cash Flow | ||||
| Op. Cash Flow | -59M | -82M | -74M | -57M |
| Free Cash Flow | -60M | -83M | -74M | -57M |
| Owner Earnings | -74M | -101M | -88M | -71M |
| CapEx | 1.6M | 1.8M | 29K | 0 |
| Maint. CapEx | 1.0M | 1.1M | 1.0M | 1.0M |
| Growth CapEx | 555K | 744K | 0 | 0 |
| D&A | 1.0M | 1.1M | 1.0M | 1.0M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 14M | 18M | 13M | 13M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -267M | -191M | -127M | -89M |
| Cash & Equiv. | N/A | N/A | N/A | 90M |
| Long-Term Debt | 9.8M | 10M | 5.1M | 5.1M |
| Debt/Equity | 0.04 | 0.05 | 0.04 | 0.02 |
| Interest Coverage | -60.1 | -71.9 | -56.9 | -56.9 |
| Equity | 270M | 188M | 117M | 83M |
| Total Assets | 300M | 221M | 145M | 98M |
| Total Liabilities | 30M | 34M | 28M | 15M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -249M | -351M | -434M | -434M |
| Working Capital | 275M | 189M | 117M | 117M |
| Current Assets | 286M | 207M | 137M | 137M |
| Current Liabilities | 11M | 18M | 20M | 20M |
| Per Share Data | ||||
| EPS | -10.10 | -14.04 | -11.49 | -8.44 |
| Owner EPS | -10.93 | -13.90 | -12.11 | -9.65 |
| Book Value | 39.94 | 25.85 | 16.04 | 11.33 |
| Cash Flow/Share | -8.71 | -11.25 | -10.18 | -8.28 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 6.8M | 7.3M | 7.3M | 7.3M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -0.9 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 1.7 | 0.4 | 0.4 | 0.6 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | -13.6% | -117.4% | -153.4% | -105.1% |
| Market Cap | 446M | 71M | 48M | 54M |
| Avg. Price | 101.87 | 28.05 | 7.54 | 7.36 |
| Year-End Price | 66.00 | 9.80 | 6.64 | 7.36 |
Kezar Life Sciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Kezar Life Sciences, Inc. (KZR) has a 5-year average return on invested capital (ROIC) of -48.2%. This is below average and may indicate limited pricing power.
Kezar Life Sciences, Inc. (KZR) has a market capitalization of $54M. It is classified as a small-cap stock.
Kezar Life Sciences, Inc. (KZR) does not currently pay a regular dividend.
Kezar Life Sciences, Inc. (KZR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Kezar Life Sciences, Inc. (KZR) generated $-74 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kezar Life Sciences, Inc. (KZR) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
Kezar Life Sciences, Inc. (KZR) reported earnings per share (EPS) of $-11.49 in its most recent fiscal year.
Kezar Life Sciences, Inc. (KZR) has a return on equity (ROE) of -55.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Kezar Life Sciences, Inc. (KZR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kezar Life Sciences, Inc. (KZR) has a book value per share of $16.04, based on its most recent annual SEC filing.